HONG KONG – China is speeding up approval times and improving the review process for domestic and imported drugs. The ultimate aim of a series of reforms announced this week by the State Council, akin to the cabinet, is to develop a faster and better approvals system that rewards innovation.

HONG KONG – An unexpected and large drop last week in the reference rate for the value of the Chinese renminbi (RMB) underscored the pressures that companies are facing in a market that remains key to both business and global economic growth.

HONG KONG – An unexpected and large drop this week in the reference rate for the value of the Chinese renminbi (RMB) underscored the pressures that companies are facing in a market that remains key to both business and global economic growth.

HONG KONG – The CFDA is getting closer to completing a new revision of the country's Pharmaceutical Administration Law. After drastically increasing the registration fees for pharmaceuticals this year, the CFDA is now soliciting opinions on a draft guideline for the registration inspection of imported pharmaceutical products.

HONG KONG – The CFDA is getting closer to completing a new revision of the country's Pharmaceutical Administration Law. After drastically increasing the registration fees for pharmaceuticals this year, the CFDA is now soliciting opinions on a draft guideline for the registration inspection of imported pharmaceutical products.

HONG KONG – Newly listed Chinese biopharmaceutical company Shenyang-based 3SBio Inc. acquired small-molecule maker Zhejiang Wansheng Pharmaceutical Co. Ltd. for ¥528 million (US$85 million) to complement its oncology and nephrology pipeline.